Alphamab Oncology (FRA:3NK)

Germany · Delayed Price · Currency is EUR

0.7200

0.00 (0.00%)

Last updated: Oct 23, 2026, 8:04 AM CEST

Market Cap	731.19M -47.9%
Revenue (ttm)	66.75M -34.1%
Net Income	-22.68M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	29.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,600
Open	0.7200
Previous Close	0.7200
Day's Range	0.7200 - 0.7200
52-Week Range	0.6950 - 1.3300
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Alphamab Oncology

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) tha... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2008

Employees 515

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 3NK

Financial Performance

Financial numbers in CNY Financial Statements